Skip to main content

Table 2 Clinical details

From: Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

  UC Total UC Rem UC Res UC NRes Control
Characteristics n = 38 n = 19 n = 9 n = 10 n = 37
Gender (male/female) 18/20 9/10 4/5 5/5 18/19
Age, years (mean, range) 39 (20–66) 41 (20–66) 38 (23–65) 37 (21–54) 42 (26–63)
Age at diagnosis (≤25/> 25 years) 15/23 5/14 4/5 6/4
Years with disease (≤10/> 10 years) 24/14 10/9 6/3 8/2
Mayo-score (mean, range) 7 (3–12) 6 (3–12) 8 (6–11) 7 (5–10)
Extension (P, PS, LC, PC) 2/8/5/23 1/7/1/10 0/1/1/7 1/0/3/6
Surgery/no surgery 2/36 1/18 0/9 1/9
Smoking/non-smoking 2/36 1/18 1/8 0/10 0/37
EIM (present/not present) 0/38 0/19 0/9 0/10
Steroids, n     
Independent/dependent/responder 1/32/5 1/17/1 0/8/1 0/7/3
Daily medication, n     
Systemic 5-aminosalicylic acid (1.6–3.2 g) 29 13 7 9
Topical 5-aminosalicylic acid (1 g) 1 1 0 0
Systemic glucocorticoids (75 mg)a 18 9 4 5
Topical glucocorticoids (100 mg) 1 1 0 0
Azathioprine (100–150 mg) 25 14 5 5
None 0 0 0 0 37
  1. aTappering regime
  2. EIM extra-intestinal manifestations, LC left-sided colitis, NRes non-responder, P proctitis, PC pancolitis, PS proctosigmoiditis, Rem remission, Res responder